MX2018006370A - Inhibidores de proteina quinasa, metodo de preparacion y su uso medico. - Google Patents
Inhibidores de proteina quinasa, metodo de preparacion y su uso medico.Info
- Publication number
- MX2018006370A MX2018006370A MX2018006370A MX2018006370A MX2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A MX 2018006370 A MX2018006370 A MX 2018006370A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- present
- preparation
- medical use
- mesomer
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 239000000203 mixture Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002547 new drug Substances 0.000 abstract 1
- 238000009522 phase III clinical trial Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención proporciona compuestos como se muestran en la fórmula I o un tautómero, un mesómero, un racemato, un enantiómero, un diastereómero, un compuesto deuterado, un profármaco o sus mezclas, o una sal o solvato aceptable farmacéuticamente del compuesto como se muestran en la fórmula I o un tautómero, un mesómero, un racemato, un enantiómero, un diastereómero, un compuesto deuterado, un profármaco o sus mezclas, en donde, R1 a R7 son tal como se definen en la descripción. La presente invención proporciona además un método de preparación y un uso médico de los compuestos. Los compuestos de la presente invención tienen una actividad superior o equivalente al fármaco candidato LY2835219 actualmente en ensayo clínico de fase III, y algunos de los compuestos muestran una selectividad mejor. Además, los compuestos preferidos exhiben una absorción buena y una distribución de sangre cerebral buena cuando se administran por vía oral. Los compuestos de la presente invención muestran de este modo una promesa para el desarrollo de nuevos fármacos para el tratamiento de enfermedades asociadas con la proliferación celular, particularmente tumores cerebrales, que proporcionan nuevas opciones para los médicos y los pacientes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510856641.1A CN106810536A (zh) | 2015-11-30 | 2015-11-30 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| PCT/CN2016/107455 WO2017092635A1 (zh) | 2015-11-30 | 2016-11-28 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018006370A true MX2018006370A (es) | 2018-09-24 |
| MX387207B MX387207B (es) | 2025-03-18 |
Family
ID=58796287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006370A MX387207B (es) | 2015-11-30 | 2016-11-28 | Inhibidores de proteína quinasa, método de preparación y su uso médico. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11091476B2 (es) |
| EP (1) | EP3385262B1 (es) |
| JP (2) | JP6921101B2 (es) |
| KR (1) | KR20180083421A (es) |
| CN (3) | CN106810536A (es) |
| AU (1) | AU2016365366B2 (es) |
| BR (1) | BR112018010879A2 (es) |
| CA (1) | CA3002884A1 (es) |
| CO (1) | CO2018005854A2 (es) |
| DK (1) | DK3385262T3 (es) |
| ES (1) | ES2928169T3 (es) |
| HU (1) | HUE060152T2 (es) |
| IL (1) | IL259711B (es) |
| MA (1) | MA42341B2 (es) |
| MX (1) | MX387207B (es) |
| PH (1) | PH12018550049A1 (es) |
| PT (1) | PT3385262T (es) |
| RU (1) | RU2749437C2 (es) |
| UA (1) | UA124001C2 (es) |
| WO (1) | WO2017092635A1 (es) |
| ZA (1) | ZA201803531B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| JP7100125B2 (ja) | 2017-10-27 | 2022-07-12 | フレゼニウス・カビ・オンコロジー・リミテッド | リボシクリブおよびその塩の改善された調製のためのプロセス |
| EP3752491A4 (en) | 2018-02-15 | 2021-12-01 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS |
| WO2019170055A1 (zh) * | 2018-03-05 | 2019-09-12 | 上海海和药物研究开发有限公司 | 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途 |
| EP3917532A4 (en) * | 2019-01-29 | 2022-09-28 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| US20220315532A1 (en) | 2019-06-21 | 2022-10-06 | Gan & Lee Pharmaceuticals Co., Ltd. | Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof |
| AR119184A1 (es) * | 2019-06-21 | 2021-12-01 | Gan & Lee Pharmaceuticals | Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas |
| WO2022042738A1 (zh) * | 2020-08-31 | 2022-03-03 | 甘李药业股份有限公司 | 一种含cdk4/6抑制剂的药物组合物 |
| CN116583283A (zh) * | 2020-09-21 | 2023-08-11 | 普莱鲁德疗法有限公司 | Cdk抑制剂及其作为药物的用途 |
| MX2023007265A (es) * | 2020-12-18 | 2023-08-14 | Prelude Therapeutics Inc | Inhibidores de cdk y su uso como productos farmacéuticos. |
| CN112390793B (zh) * | 2021-01-19 | 2021-04-27 | 中国药科大学 | Cdk6/dyrk2双靶点抑制剂及其制备方法和应用 |
| WO2022218247A1 (zh) * | 2021-04-12 | 2022-10-20 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
| WO2022242563A1 (zh) * | 2021-05-17 | 2022-11-24 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| CN118119393A (zh) * | 2021-09-14 | 2024-05-31 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
| WO2023116862A1 (zh) * | 2021-12-24 | 2023-06-29 | 江苏恒瑞医药股份有限公司 | 氢化吲哚类化合物、其制备方法及其在医药上的应用 |
| CN115093397B (zh) * | 2022-06-07 | 2023-09-05 | 自贡市第三人民医院 | 一种用于治疗肿瘤的化合物、合成方法及应用 |
| WO2024051717A1 (zh) * | 2022-09-08 | 2024-03-14 | 上海深势唯思科技有限责任公司 | 作为plk1抑制剂的化合物及其制备方法和用途 |
| WO2024066986A1 (zh) * | 2022-09-30 | 2024-04-04 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| JP2003521543A (ja) | 2000-02-07 | 2003-07-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用 |
| GEP20063909B (en) * | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| JP2007520558A (ja) | 2004-02-04 | 2007-07-26 | スミスクライン・ビーチャム・コーポレイション | キナーゼ阻害剤として有用なピリミジノン化合物 |
| CA2640398A1 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
| WO2008124085A2 (en) * | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) * | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| HRP20170317T1 (hr) * | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| AU2009248233A1 (en) | 2008-05-16 | 2009-11-19 | F. Hoffmann-La Roche Ag | Inhibitors of JNK |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33227A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN106608879A (zh) | 2015-10-27 | 2017-05-03 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| CN106810536A (zh) | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
| KR102765806B1 (ko) | 2017-09-05 | 2025-02-10 | 블랙손 테라퓨틱스, 인크. | 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법 |
| WO2022218247A1 (zh) | 2021-04-12 | 2022-10-20 | 甘李药业股份有限公司 | 作为cdk4/6抑制剂的氘代化合物 |
-
2015
- 2015-11-30 CN CN201510856641.1A patent/CN106810536A/zh active Pending
-
2016
- 2016-11-28 AU AU2016365366A patent/AU2016365366B2/en not_active Ceased
- 2016-11-28 MA MA42341A patent/MA42341B2/fr unknown
- 2016-11-28 MX MX2018006370A patent/MX387207B/es unknown
- 2016-11-28 PT PT168699452T patent/PT3385262T/pt unknown
- 2016-11-28 IL IL259711A patent/IL259711B/en unknown
- 2016-11-28 UA UAA201806447A patent/UA124001C2/uk unknown
- 2016-11-28 CN CN201680064053.7A patent/CN108290864B/zh active Active
- 2016-11-28 WO PCT/CN2016/107455 patent/WO2017092635A1/zh not_active Ceased
- 2016-11-28 EP EP16869945.2A patent/EP3385262B1/en active Active
- 2016-11-28 RU RU2018122864A patent/RU2749437C2/ru active
- 2016-11-28 CA CA3002884A patent/CA3002884A1/en active Pending
- 2016-11-28 HU HUE16869945A patent/HUE060152T2/hu unknown
- 2016-11-28 BR BR112018010879-0A patent/BR112018010879A2/pt not_active Application Discontinuation
- 2016-11-28 ES ES16869945T patent/ES2928169T3/es active Active
- 2016-11-28 JP JP2018546737A patent/JP6921101B2/ja not_active Expired - Fee Related
- 2016-11-28 CN CN202111217526.1A patent/CN113956238B/zh active Active
- 2016-11-28 US US15/778,812 patent/US11091476B2/en not_active Expired - Fee Related
- 2016-11-28 DK DK16869945.2T patent/DK3385262T3/da active
- 2016-11-28 KR KR1020187017438A patent/KR20180083421A/ko active Pending
-
2018
- 2018-04-23 PH PH12018550049A patent/PH12018550049A1/en unknown
- 2018-05-28 ZA ZA2018/03531A patent/ZA201803531B/en unknown
- 2018-06-06 CO CONC2018/0005854A patent/CO2018005854A2/es unknown
-
2021
- 2021-06-08 JP JP2021095588A patent/JP2021138737A/ja active Pending
- 2021-07-30 US US17/444,109 patent/US11787801B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018006370A (es) | Inhibidores de proteina quinasa, metodo de preparacion y su uso medico. | |
| CY1123616T1 (el) | 7-βενζυλ-4-(4-(τριφθορομεθυλ)βενζυλ)-1,2,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(4η)-ονη, και αλατα αυτης και χρηση αυτων στη θεραπεια | |
| UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| DOP2010000011A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| MX375282B (es) | Pirrolo[2,3-c]piridinas como agentes de formacion de imagenes para ovillos neurofibrilares. | |
| NI201300082A (es) | Métodos de tratamiento del cáncer utilizando 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona. | |
| ECSP109934A (es) | Compuesto - 946 | |
| RU2017145646A (ru) | Производное пиперидина, способ его получения и его фармацевтическое применение | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| EA201200260A1 (ru) | Гетероциклические гидразоны и их применение для лечения рака и воспаления | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX2019004484A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| AR112284A1 (es) | Combinación que comprende palbociclib y ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxílico | |
| MX387785B (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos. | |
| UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| BR112022010181A2 (pt) | Composto tri-heterocíclico como inibidor de jak e uso do mesmo | |
| SV2011004017A (es) | Tratamiento del cancer de pancreas | |
| BR112015024472A2 (pt) | derivados de quinolina multifuncionais como agentes anti-neurodegenerativos |